EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Empagliflozin in STEMI Patients: A Randomized Controlled Trial on Left Ventricular Recovery and Cardiovascular Outcomes

Fatemeh Baharvand, Roxana Mehran, Francesca Maria Di Muro, Alieh Mohammadi, Mohammadreza Aghajankhah, Shiva Parvaneh, Niloufar Akbari Parsa, Soheil Hassanipour, Ehsan Aboutaleb, Yaser Jenab, Somayeh Bashiri Aliabadi

American Journal of Cardiovascular Drugs · 2026-09 · 26 (5) · 631-644

DOI: 10.1007/s40256-026-00814-8 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Cardiovascular Drugs, online erschienen am 17.07.2026. Verfasst von Fatemeh Baharvand und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Healthy Heart Research Center, Heshmat Hospital, School of medicine, Guilan University of Medical Sciences, Rasht, Iran. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, ST Elevation Myocardial Infarction, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide cardiovascular benefits in diabetes, but their role in the acute post-myocardial infarction (MI) setting is uncertain. This study evaluated the association of empagliflozin with left ventricular ejection fraction (LVEF) recovery and major adverse cardiac events (MACE) in patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). METHODS: In a single-center, double-blind, randomized, placebo-controlled trial, patients with STEMI were randomized to empagliflozin 10 mg or placebo daily for 40 days. The primary endpoint was change in left ventricular ejection fraction (LVEF) from baseline to day 40, with sample size calculated a priori based on data from the EMMY trial (minimum 27 per group; 53 per group enrolled). Major adverse cardiac events (MACE)-defined as cardiovascular death, myocardial infarction, or stroke-were assessed as a secondary exploratory endpoint. RESULTS: A total of 117 patients were randomized (59 empagliflozin, 58 placebo), of whom 106 completed follow-up and were analyzed (53 per group). Empagliflozin was associated with significantly greater LVEF recovery at day 40 (mean increase: 7.35% ± 6.11% versus 2.96% ± 5.49%; mean difference 4.39%, 95% CI 2.09-6.70%; P = 0.000272), which remained significant after adjustment for baseline LVEF, age, sex, and diabetes status (adjusted difference: 3.44%, 95% CI 1.22-5.66%; P = 0.003; Cohen's d = 0.756). The benefit was numerically greater in younger and nondiabetic patients, though no subgroup interaction reached significance after multiplicity correction. MACE did not differ significantly between groups (3.8 versus 7.5%; P = 0.68), with no recurrent MI or stroke in either group. Adverse events were rare and comparable, with no diabetic ketoacidosis, amputation, or acute kidney injury observed. CONCLUSIONS: In this preliminary single-center trial, empagliflozin was associated with significantly greater LVEF recovery in patients with STEMI after PCI, with effects robust to covariate adjustment, and without increasing adverse events. Although MACE was not significantly reduced-as expected given the study was not powered for hard clinical events-the LVEF improvement represents a promising early prognostic signal. These findings are applicable to lower-risk patients with STEMI with successful reperfusion and may not generalize to higher-risk patients with failed PCI or hemodynamic compromise. Larger, adequately powered, long-term multicenter trials are needed to confirm clinical benefits. TRIAL REGISTRATION: Registered at the Iranian Registry of Clinical Trials identifier no. IRCT20220809055645N7.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesST Elevation Myocardial InfarctionSodium-Glucose Transporter 2 InhibitorsVentricular Function, LeftHumansFemaleDouble-Blind MethodMaleMiddle AgedStroke VolumeAgedPercutaneous Coronary InterventionTreatment Outcome

Substanzen

empagliflozinBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Cardiology, Healthy Heart Research Center, Heshmat Hospital, School of medicine, Guilan University of Medical Sciences, Rasht, Iran.
  • The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
  • Department of Pharmaceutics, School of pharmacy, Guilan University of Medical Sciences, Rasht, Iran.
  • Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. yasjenab@gmail.com.

Zitieren

APA

Baharvand, F., Mehran, R., Di Muro, F. M., Mohammadi, A., Aghajankhah, M., Parvaneh, S., Parsa, N. A., Hassanipour, S., Aboutaleb, E., Jenab, Y., & Aliabadi, S. B. (2026). Empagliflozin in STEMI Patients: A Randomized Controlled Trial on Left Ventricular Recovery and Cardiovascular Outcomes. American Journal of Cardiovascular Drugs, 26(5), 631-644. https://doi.org/10.1007/s40256-026-00814-8

Vancouver

Baharvand F, Mehran R, Di Muro FM, Mohammadi A, Aghajankhah M, Parvaneh S, et al. Empagliflozin in STEMI Patients: A Randomized Controlled Trial on Left Ventricular Recovery and Cardiovascular Outcomes. American Journal of Cardiovascular Drugs. 2026;26(5):631-644. doi:10.1007/s40256-026-00814-8

BibTeX
@article{Baharvand2026,
  author = {Baharvand, Fatemeh and Mehran, Roxana and Di Muro, Francesca Maria and Mohammadi, Alieh and Aghajankhah, Mohammadreza and Parvaneh, Shiva and Parsa, Niloufar Akbari and Hassanipour, Soheil and Aboutaleb, Ehsan and Jenab, Yaser and Aliabadi, Somayeh Bashiri},
  title = {Empagliflozin in STEMI Patients: A Randomized Controlled Trial on Left Ventricular Recovery and Cardiovascular Outcomes},
  journal = {American Journal of Cardiovascular Drugs},
  year = {2026},
  volume = {26},
  number = {5},
  pages = {631--644},
  doi = {10.1007/s40256-026-00814-8}
}
Kostenlos starten →